DE69434115D1 - Inhibitor des wachstumsfaktors für gefäss-endothelzellen - Google Patents

Inhibitor des wachstumsfaktors für gefäss-endothelzellen

Info

Publication number
DE69434115D1
DE69434115D1 DE69434115T DE69434115T DE69434115D1 DE 69434115 D1 DE69434115 D1 DE 69434115D1 DE 69434115 T DE69434115 T DE 69434115T DE 69434115 T DE69434115 T DE 69434115T DE 69434115 D1 DE69434115 D1 DE 69434115D1
Authority
DE
Germany
Prior art keywords
growth factor
inhibitor
vessel
vegf
soluble forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69434115T
Other languages
English (en)
Other versions
DE69434115T2 (de
Inventor
Richard L Kendall
Kenneth A Thomas Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69434115D1 publication Critical patent/DE69434115D1/de
Application granted granted Critical
Publication of DE69434115T2 publication Critical patent/DE69434115T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69434115T 1993-03-25 1994-02-25 Inhibitor des wachstumsfaktors für gefässendothelzellen Expired - Fee Related DE69434115T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3876993A 1993-03-25 1993-03-25
US38769 1993-03-25
PCT/US1994/001957 WO1994021679A1 (en) 1993-03-25 1994-02-25 Inhibitor of vascular endothelial cell growth factor

Publications (2)

Publication Number Publication Date
DE69434115D1 true DE69434115D1 (de) 2004-12-09
DE69434115T2 DE69434115T2 (de) 2005-10-27

Family

ID=21901791

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434115T Expired - Fee Related DE69434115T2 (de) 1993-03-25 1994-02-25 Inhibitor des wachstumsfaktors für gefässendothelzellen

Country Status (12)

Country Link
US (5) US5712380A (de)
EP (1) EP0694042B1 (de)
JP (1) JP3734262B2 (de)
AT (1) ATE281469T1 (de)
AU (1) AU684498B2 (de)
CA (1) CA2158745C (de)
DE (1) DE69434115T2 (de)
DK (1) DK0694042T3 (de)
ES (1) ES2230542T3 (de)
IL (1) IL109016A (de)
PT (1) PT694042E (de)
WO (1) WO1994021679A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6710174B2 (en) * 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE69733204T3 (de) 1996-07-15 2012-03-08 Chugai Seiyaku K.K. Neuartige vegf-ähnliche faktoren
JP2001501471A (ja) * 1996-09-24 2001-02-06 メルク エンド カンパニー インコーポレーテッド 血管新生の阻害のための遺伝子治療
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
EP1086705A4 (de) * 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk Inhibitoren der aktivität des vaskularen endothelialen wachstumsfaktors
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
CA2359461A1 (en) * 1999-01-15 2000-07-20 Medstar Research Institute Inhibiting development of microvessels within vascular walls
US7303746B2 (en) * 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
GB9928950D0 (en) * 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
US20030036524A1 (en) * 2000-03-08 2003-02-20 Jens Licthenberg Method of sensitising endothelial cells to prodrugs
EP1581615B1 (de) 2000-09-05 2010-04-28 Biosight Ltd Peptid-konjugierte antikrebs-prodrugs
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
AU2003215163A1 (en) * 2002-02-12 2003-09-04 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
US20040101478A1 (en) * 2002-03-29 2004-05-27 Thomas Kenneth A In vivo methods of determining activity of receptor-type kinase inhibitors
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
CN103073620B (zh) * 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US7432341B2 (en) * 2002-10-24 2008-10-07 Valo Hsj, Limited Partnership Cytokine receptor modulators and method of modulating cytokine receptor activity
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
AU2004265226A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
JP4680997B2 (ja) * 2004-06-08 2011-05-11 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド 血管新生を阻害するキメラタンパク質およびその利用
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
EP1804835B9 (de) 2004-09-13 2010-09-29 Genzyme Corporation Multimere konstrukte
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
EP2289533B1 (de) 2005-02-28 2013-09-18 Oncotherapy Science, Inc. Aus vaskulärem Endothelwachstumsfaktor-Rezeptor 1 gewonnene Epitoppeptide und Impfstoffe mit diesen Peptiden
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
WO2007009071A2 (en) * 2005-07-13 2007-01-18 Beth Israel Deaconess Medical Center Methods of diagnosing and treating an inflammatory response
US9198981B2 (en) * 2006-02-01 2015-12-01 The University Of Kentucky Modulation of angiogenesis
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
RU2010133157A (ru) 2008-01-07 2012-02-20 Орто-Клиникал Дайэгностикс, Инк. (Us) Определение комплекса sflt-1:ангиогенный фактор
WO2009149205A2 (en) * 2008-06-03 2009-12-10 Neurotech Usa, Inc. Cell lines that secrete soluble vegf receptors and uses thereof
WO2010091234A2 (en) 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
AU2014205369B2 (en) 2013-01-11 2018-08-09 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
EP2994758B1 (de) 2013-05-08 2017-12-20 Opthea Limited Biomarker für altersbedingte makuladegeneration (amd)
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015231439B2 (en) 2014-03-17 2019-11-14 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
KR101819135B1 (ko) 2014-03-18 2018-01-18 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (de) 2014-07-18 2019-04-10 Sanofi Verfahren zur vorhersage des ausgangs einer behandlung mit aflibercept bei einem patienten mit verdacht auf ein krebsleiden
KR20170137730A (ko) 2015-03-02 2017-12-13 애드베룸 바이오테크놀로지스, 인코포레이티드 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
AU2017257169B2 (en) 2016-04-29 2021-07-08 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
WO2017218981A2 (en) 2016-06-16 2017-12-21 Adverum Biotechnologies, Inc. Compositions and methods for reducing ocular neovascularization
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018170473A1 (en) 2017-03-17 2018-09-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
WO2019147944A1 (en) 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
JP7384815B2 (ja) * 2018-03-22 2023-11-21 ザ チルドレンズ メディカル センター コーポレーション 肺の修復に関する方法および組成物
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
JP2024519888A (ja) 2021-05-28 2024-05-21 上海瑞宏迪医薬有限公司 カプシド変異を有する組換えアデノ随伴ウイルス及びその応用
CA3233983A1 (en) * 2021-11-02 2023-05-11 Ole-Jan Iversen (Deceased) Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49753A1 (en) * 1991-02-22 1998-06-15 American Cyanamid Co Identification of a novel human receptor tyrosine kinase gene
DE69233739D1 (de) * 1992-10-28 2008-08-07 Genentech Inc Verwendung von Antagonisten des Zellwachstumsfaktors VEGF
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1

Also Published As

Publication number Publication date
JPH08508161A (ja) 1996-09-03
US7071159B2 (en) 2006-07-04
US5861484A (en) 1999-01-19
JP3734262B2 (ja) 2006-01-11
CA2158745A1 (en) 1994-09-29
EP0694042A4 (de) 2001-05-02
EP0694042A1 (de) 1996-01-31
AU684498B2 (en) 1997-12-18
US5712380A (en) 1998-01-27
WO1994021679A1 (en) 1994-09-29
PT694042E (pt) 2005-02-28
US20030120038A1 (en) 2003-06-26
US8034772B2 (en) 2011-10-11
ATE281469T1 (de) 2004-11-15
EP0694042B1 (de) 2004-11-03
DK0694042T3 (da) 2005-02-14
US20090247460A1 (en) 2009-10-01
AU6393494A (en) 1994-10-11
CA2158745C (en) 2007-06-19
DE69434115T2 (de) 2005-10-27
ES2230542T3 (es) 2005-05-01
IL109016A0 (en) 1994-06-24
US20070010442A1 (en) 2007-01-11
IL109016A (en) 2005-07-25

Similar Documents

Publication Publication Date Title
DE69434115D1 (de) Inhibitor des wachstumsfaktors für gefäss-endothelzellen
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE69434908D1 (de) Rezeptor an der oberfläche von aktivierten t-zellen:act4
ATE272114T1 (de) Rezeptoren für il-18
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
DK0930365T3 (da) Bindingsdomæner i Serrate-protein
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
NZ516258A (en) Tek antagonists
BR9407377A (pt) Toxina hibrida
NO982715D0 (no) Endotel celle-proliferasjonsinhibitor og fremgangsmÕte for anvendelse
NO960939D0 (no) Kininogenaseinhibitor
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
GR3029483T3 (en) Antibodies against t-cells as therapeutics
DK0594576T3 (da) Immunoafprøvninger for og monoklonale antistoffer over for prothrombin-aktivering-peptider og deres nedbrydningsprodukter
ATE288280T1 (de) Verfahren zum blokieren von sec-rezeptoren
DK1268823T3 (da) Fremgangsmåder og celler til ekspression af rekombinante proteinprodukter
GB2342652A (en) Polypeptides comprising a coiled-coil and an addition
ATE394419T1 (de) Peptidantagonisten von dp transkriptionsfaktoren
AU2434400A (en) Method for the cellular high-throughput-detection of nuclear receptor ligand interactions
DK0583352T3 (da) hGPIIB fragmenter og deres anvendelse i in vitro metoder til bestemmelse af in vivo thrombotiske tilstande
WO1996023883A3 (en) Modified ligands for receptor tyrosine kinases
DE59813016D1 (de) Cadherin derived growth factor und seine verwendung
NO984522L (no) Monoklonale antistoffer som binder humant veksthormon (hGH)
Nebigil Characterization and second messenger systems of alpha adrenergic receptor subtypes involved in prostaglandin production in vascular smooth muscle cells of rabbit aorta.
EP0367554A3 (de) Insulinbindende Wirkstoffe und Hemmer der Insulinbindung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee